{"id":681862,"date":"2023-12-19T19:14:01","date_gmt":"2023-12-19T19:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=681862"},"modified":"2023-12-19T19:14:01","modified_gmt":"2023-12-19T19:14:01","slug":"crispr-therapies-pipeline-fda-approvals-clinical-trials-developments-and-companies-2023-updated","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/crispr-therapies-pipeline-fda-approvals-clinical-trials-developments-and-companies-2023-updated_681862.html","title":{"rendered":"CRISPR Therapies Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1703003577.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"CRISPR Therapies Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)\" src=\"https:\/\/www.abnewswire.com\/uploads\/1703003577.png\" alt=\"CRISPR Therapies Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>CRISPR Therapies Pipeline Insight 2023<\/strong>&rdquo; report provides comprehensive insights about 25+ CRISPR Therapies Companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CRISPR Therapies therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive CRISPR Therapies pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the CRISPR Therapies Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s CRISPR Therapies pipeline report depicts a robust space with 25+ CRISPR Therapies companies working to develop 25+ pipeline therapies for CRISPR Therapies treatment.<\/li>\n<li>The leading CRISPR Therapies Companies working in the market include <em>Intellia Therapeutics, CRISPR therapeutics, Repare Therapeutics, Beam therapeutics, Caribou Biosciences, Emendo Biotherapeutics, Defence Therapeutics, Sarepta therapeutics, Editas Medicine, Locus Biosciences, Excision BioTherapeutics, AstraZeneca, Novartis, ASC therapeutics, Casebia therapeutics, Spotlight Therapeutics, KSQ Therapeutics, MEDIC Life Sciences, Scribe therapeutics, Arbor Biotechnologies, Sangamo therapeutics, Graphite Bio, Nuntius Therapeutics<\/em>, and others.<\/li>\n<li>Promising CRISPR Therapies in the various stages of development include <em>BD111 Adult single group Dose, HG202, CB-011, Cyclophosphamide, Fludarabine, Aldesleukin, EBT-101<\/em>, and others.<\/li>\n<li><strong><em>November 2023: HuidaGene Therapeutics Co. Ltd<\/em><\/strong>. announced a study of early phase 1 clinical trials for HG202. A Trial to Evaluate the Safety, Tolerability, and Efficacy of CRISPR-Cas13 RNA-editing Therapy Targeting Knockdown of Vascular Endothelial Growth Factor A (HG202) in the Treatment of Neovascular Age-related Macular Degeneration (nAMD).<\/li>\n<li><strong><em>November 2023: Caribou Biosciences Inc<\/em><\/strong>. announced a study of Phase 1 clinical trials for CB-011. This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in CRISPR Therapies Treatment Drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/crispr-therapies-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">CRISPR Therapies Pipeline Outlook Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The CRISPR Therapies pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage CRISPR Therapies drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the CRISPR Therapies clinical trial landscape.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>CRISPR Therapies Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">CRISPRs are specialized stretches of DNA. &#8220;&#8221;CRISPR&#8221;&#8221; stands for &#8220;&#8221;clusters of regularly interspaced short palindromic repeats.&#8221;&#8221; It is a specialized region of DNA with two distinct characteristics: the presence of nucleotide repeats and spacers. Repeated sequences of nucleotides &mdash; the building blocks of DNA &mdash; are distributed throughout a CRISPR region.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Find out more about CRISPR Therapies Treatment Landscape @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crispr-therapies-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Drugs for CRISPR Therapies Treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>CRISPR Therapies Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>CTX001: CRISPR Therapeutics<\/li>\n<li>EDIT-101: Editas Medicine<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>CRISPR Therapies Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 25+ key CRISPR Therapies companies which are developing the CRISPR Therapies. The CRISPR Therapies companies which have their CRISPR Therapies drug candidates in the most advanced stage, i.e. Phase I\/II include, CRISPR therapeutics.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s CRISPR Therapies Pipeline Report covers around&nbsp;30+ products&nbsp;under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>CRISPR Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical.<\/li>\n<li>Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>CRISPR Therapies Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<li>Product Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the emerging CRISPR Therapies Pipeline Therapies @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crispr-therapies-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">CRISPR Therapies Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the CRISPR Therapies Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>CRISPR Therapies Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>CRISPR Therapies Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li>CRISPR Therapies Companies- <em>Intellia Therapeutics, CRISPR therapeutics, Repare Therapeutics, Beam therapeutics, Caribou Biosciences, Emendo Biotherapeutics, Defence Therapeutics, Sarepta therapeutics, Editas Medicine, Locus Biosciences, Excision BioTherapeutics, AstraZeneca, Novartis, ASC therapeutics, Casebia therapeutics, Spotlight Therapeutics, KSQ Therapeutics, MEDIC Life Sciences, Scribe therapeutics, Arbor Biotechnologies, Sangamo therapeutics, Graphite Bio, Nuntius Therapeutics<\/em>, and others.<\/li>\n<li>CRISPR Therapies- <em>BD111 Adult single group Dose, HG202, CB-011, Cyclophosphamide, Fludarabine, Aldesleukin, EBT-101,<\/em> and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for new drugs for CRISPR Therapies treatment, Visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crispr-therapies-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">CRISPR Therapies Market Drivers and Barriers, and Future Perspective<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>CRISPR Therapies: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Drug Name: Company Name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I\/II)<\/li>\n<li>CTX001: CRISPR Therapeutics<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early stage products (Phase I)<\/li>\n<li>LBP-EC01: Locus Biosciences<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>CRISPR Therapies Key Companies<\/li>\n<li>CRISPR Therapies Key Products<\/li>\n<li>CRISPR Therapies- Unmet Needs<\/li>\n<li>CRISPR Therapies- Market Drivers and Barriers<\/li>\n<li>CRISPR Therapies- Future Perspectives and Conclusion<\/li>\n<li>CRISPR Therapies Analyst Views<\/li>\n<li>CRISPR Therapies Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information on the CRISPR Therapies pipeline therapeutics, reach out to <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crispr-therapies-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">CRISPR Therapies Unmet Needs and Analyst Views<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=crispr-therapies-pipeline-fda-approvals-clinical-trials-developments-and-companies-2023-updated\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-melanoma-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/metastatic-melanoma-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-melanoma-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=crispr-therapies-pipeline-fda-approvals-clinical-trials-developments-and-companies-2023-updated\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;CRISPR Therapies Pipeline Insight 2023&rdquo; report provides comprehensive insights about 25+ CRISPR Therapies Companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/crispr-therapies-pipeline-fda-approvals-clinical-trials-developments-and-companies-2023-updated_681862.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-681862","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/681862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=681862"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/681862\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=681862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=681862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=681862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}